# Stamford Pharmaceuticals

Source: https://onco.cc/companies/stamford-pharmaceuticals/  
OnCo record `stamford-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Stamford Pharmaceuticals injects a modified common-cold virus carrying an immune-signalling gene into skin cancers, and is testing it alongside a standard tablet for advanced basal cell carcinoma.

## Summary

Stamford Pharmaceuticals, Inc., which moved its head office to Austin, Texas in 2023, is a clinical-stage oncology company developing gene therapies for skin and visceral cancers. SP-002 is an adenoviral vector (serotype 5) that delivers the gene for interferon gamma into the tumour. A phase 2 study tests SP-002 with the hedgehog pathway inhibitor vismodegib in locally advanced basal cell carcinoma (NCT06344052); the company plans a phase 2/3 study in high-risk nodular basal cell carcinoma in 2027 and has an open IND for cutaneous squamous cell carcinoma. Its SP-500 platform conjugates the vector with small-molecule payloads, with preclinical candidates for bladder, pancreatic, head and neck, prostate and breast cancer. Its first registered cancer trial, NCT06344052, was posted on ClinicalTrials.gov in April 2024; an earlier phase 2a study of SP-002 (NCT04416516) is registered under a different sponsor name.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Stamford Pharmaceuticals, Inc.
- HQ: Austin, TX
- Type: biotech
- Website: https://stamfordpharmaceuticals.com/

## Notes

- Company website, product page and news list read on 29 October 2026. Founding year not stated. No financing round was read. The sponsor of NCT04416516 was not checked.

## Sources

- Official website: https://stamfordpharmaceuticals.com/
- Product and pipeline: https://stamfordpharmaceuticals.com/product-and-pipeline

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)
- trials: [To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma](https://onco.cc/trials/nct06344052/)

---
JSON: https://onco.cc/api/v1/entities/stamford-pharmaceuticals.json